



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification<sup>4</sup> : A61B 5/00, A61M 5/142 C12M 1/40</p>	<p>A1</p>	<p>(11) International Publication Number: <b>WO 89/02720</b> (43) International Publication Date: 6 April 1989 (06.04.89)</p>
<p>(21) International Application Number: PCT/NL88/00039 (22) International Filing Date: 5 October 1988 (05.10.88) (31) Priority Application Number: 8702370 (32) Priority Date: 5 October 1987 (05.10.87) (33) Priority Country: NL (71) Applicant (for all designated States except US): STICHTING SCIENCE PARK GRONINGEN [NL/ NL]; Zernike Park 2, NL-9747 AN Groningen (NL). (72) Inventors; and (75) Inventors/Applicants (for US only): SCHOONEN, Adel- bert, Jozef, Martinus [NL/NL]; Herman Collien- straat 24, NL-9718 KT Groningen (NL). SCHMIDT, Fransiscus, Josephus [NL/NL]; Kraneweg 64, NL- 9718 JT Groningen (NL).</p>		<p>(74) Agent: SMULDERS, Th., A., H., J.; Vereenigde Octro- oibureaux, Nieuwe Parklaan 107, NL-2587 BP The Hague (NL). (81) Designated States: AT (European patent), BE (Euro- pean patent), CH (European patent), DE (European patent), DK, FR (European patent), GB (European patent), IT (European patent), JP, LU (European pa- tent), NL (European patent), SE (European patent), US.  Published With international search report.</p>
<p>(54) Title: A PROCESS AND SYSTEM AND MEASURING CELL ASSEMBLY FOR GLUCOSE DETERMINA- TION</p> <p>(57) Abstract</p> <p>A wearable-type glucose sensor for continuously or intermittently determining the glucose content comprises a short hollow fiber (2) to be positioned in the subcutaneous tissue. This hollow fiber is connected via tubes (3, 4) with component parts (5 ... 12) located outside the body, such as a measuring unit (11). When a perfusion fluid containing the enzyme glucose oxidase is passed through the hollow fiber, a subcutaneous dialysis will take place in which some glucose dissolves in the perfusion fluid through the wall of the hollow fiber. This glucose is completely oxidized by the oxygen dissolved in the perfusion fluid in the presence of the glucose oxidase. By means of the measuring unit the resultant amount of H<sub>2</sub>O<sub>2</sub> or, preferably, the employed amount of O<sub>2</sub> is determined, both of which are a measure of the subcutaneous glucose concentration.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT Austria	FR France	ML Mali
AU Australia	GA Gabon	MR Mauritania
BB Barbados	GB United Kingdom	MW Malawi
BE Belgium	HU Hungary	NL Netherlands
BG Bulgaria	IT Italy	NO Norway
BJ Benin	JP Japan	RO Romania
BR Brazil	KP Democratic People's Republic of Korea	SD Sudan
CF Central African Republic	KR Republic of Korea	SE Sweden
CG Congo	LI Liechtenstein	SN Senegal
CH Switzerland	LK Sri Lanka	SU Soviet Union
CM Cameroon	LU Luxembourg	TD Chad
DE Germany, Federal Republic of	MG Monaco	TG Togo
DK Denmark	MG Madagascar	US United States of America
FI Finland		

A process and system and measuring cell assembly for glucose determination.

---

The invention relates to a process for continuously or intermittently determining the glucose concentration in subcutaneous tissue, which comprises using an enzymatic oxidation of glucose by oxygen in the presence of the enzyme glucose oxidase and determining the used  
5 amount of oxygen or the resultant amount of hydrogen peroxide by means of a measuring cell.

The invention further relates to a system for continuously or intermittently determining the  
10 glucose concentration in subcutaneous tissue as well as to a measuring cell assembly suitable for use in this system and to an assembly for continuously or intermittently regulating the glucose concentration in blood.

More in particular, the invention relates  
15 to a system referred to hereinafter as glucose sensor which, e.g., could be used to control wearable-type insulin pumps. At present the number of persons provided with wearable-type insulin pumps is still limited.  
20 In general, these are people with whom the classical method of injecting insulin once or twice a day cannot provide satisfactory regulation. The present wearable-type insulin pumps, however, lack the possibility of regulating the insulin dose depending on the glucose  
25 concentration in the blood. A reliable and wearable-type glucose sensor would permit a better and more comfortable regulation of the glucose concentration not only for this group of persons but also for other diabetics, and in general for persons having a need  
30 for medicines, such as insulin, depending on the glucose concentration in the blood, it would be a useful alternative.

Several research groups are engaged in the

-2-

development of a glucose sensor. One of those research groups is the group of Shichiri of the "First Department of Medicine" at the university of Osaka, Japan. This group succeeded [see Diabetologia 24 (1983) 179-184; Biomed. Biochim. Acta 43 (1984), 561-568; Diabetes Care 9 (1986) 298-301] in developing a glucose sensor capable of measuring the glucose concentration in subcutaneous tissue for three days. The small needle-type glucose sensor consists of a platinum electrode covered with immobilized enzyme glucose oxidase. In the reaction of glucose with oxygen in the presence of the enzyme  $H_2O_2$  is released which can be measured by this electrode and is a measure of the amount of glucose present. In vitro the electrode gives a current of  $1.2 \pm 0.4$  nA in a 5.5 mmol/l glucose solution. The current is linear with the glucose concentrations, and the time required to obtain 90% of the plateau value is  $16.2 \pm 6.2$  sec.

In the first instance, subcutaneous measurements were carried out in dogs, the response sustaining a delay of 5-15 minutes with respect to the direct measurement in blood. The sensitivity of the electrode gradually decreases to  $57.4 \pm 7\%$  of the initial value after 96 hours measurement. This loss of signal, due to the rapid breakdown of the enzyme, causes that the subcutaneously inserted sensor must be replaced at least every three days.

Finally, Shichiri developed a completely wearable artificial endocrine pancreas (12x15x6 cm, 400 g) consisting of the sensor, a microcomputer which calculates the required infusion rate of insulin, and a dual-syringe driving system. This apparatus is capable of regulating the blood glucose concentration in depancreatized dogs for three days. Then Shichiri proceeded in measurement in subcutaneous tissue of diabetics. The subcutaneously measured glucose values are, on an average, 10% lower than those of blood, but there is a good correlation between the two values in the range of from 60 to 400 mg/dl

-3-

glucose. The complete artificial pancreas was then tested out on diabetics, using a self-developed subcutaneous insulin infusion algorithm. Mention is only made of one representative patient in which the glucose was regulated with the sensor for two days.

Another research group was directed by M. Kessler of the institute for physiology and cardiology of the university of Erlangen-Nuremberg. The glucose sensor developed there [Hepato-gastroenterol. 31 (1984) 285-288] also functions via an enzymatic conversion of glucose by means of glucose oxidase, followed by measuring the resulting  $H_2O_2$ . This purpose is served by using an electrode with a gold anode covered with three membranes. A dialysis membrane permeable to glucose, gases and inorganic ions but impermeable to larger molecules, such as proteins, functions as a selector. Provided therebelow is an enzyme membrane functioning as a kind of reaction space. Contained therein is the immobilized enzyme glucose oxidase. A sealing lipophilic membrane with incorporated proton carrier molecules is closest to the gold anode. The glucose diffusing through the dialysis membrane reacts in the presence of the enzyme with oxygen, thus forming  $H_2O_2$ . The  $H_2O_2$  is oxidized at the gold anode so as to form 2 protons. These are eliminated by the proton carriers. With this sensor Kessler carried out measurements in the peritoneum of anesthetized rats. He found a good correlation between the glucose values measured in the peritoneum and the real blood glucose values. Dimensions of the electrode are not mentioned, but an electrode suitable for implantation in human beings is not yet available.

A. Müller and P. Abel of the Zentralinstitut für Diabetes "Gerhardt Katsch" from Karlsberg (GDR) also have a glucose oxidase/ $H_2O_2$  sensor available [Biomed. Biochim. Acta 43 (1984) 577-584; Biomed. Biochim. Acta 45 (1986) 769-777]. Again the immobilized enzyme is fixed to the electrode (Pt) surface. This is spanned by respectively a hydrophobic and a hydrophilic membrane

-4-

as a selector for the glucose. After a starting period of 24 hours this electrode gives a stable signal, i.e. a current of 0.02-6.8 nA, according to the glucose concentration. It is 7 cm in length and has a diameter of 2-4 mm. The electrode was implanted in 6 dogs and the glucose was measured. The ratio between glucose concentrations in blood and in tissue then varies from 33 to 70%. Besides this large spreading, failures occur frequently so that a good in vivo calibration is not possible.

All the glucose sensors hitherto developed that have already reached the experimental in vivo stage are therefore based on a system with immobilized enzyme glucose oxidase. This has the advantage that the electrode can be miniaturized and readily implanted in whole. However, an important drawback is that under those conditions the enzyme is stable for a very short time only and that consequently frequent replacement (3-4 days) of the electrode is necessary. Another requirement in the technique of immobilization is that each electrode must be calibrated individually and that it takes a day before the electrode can give a stable signal.

In EP-A 0 134 758 Bombardieri also describes a glucose sensor starting from the same principle as the above discussed sensors: the selector is a membrane on which the enzyme glucose oxidase is immobilized. However, he does not provide the glucose sensor subcutaneously as the other authors do, but he connects the sensor to a perfusion system which uses long and/or many hollow fibers inserted into subcutaneous tissue to transport low-molecular substances, inter alia glucose, in the same concentrations as prevailing subcutaneously from said tissue to a place outside the body. The advantage of this method is that the membrane with immobilized enzyme can be easily replaced without requiring anything to be done subcutaneously. The drawback of this method as compared with, e.g., the

-5-

Shichiri electrode is that the extensive hollow fiber package is to be applied surgically by making an incision in the skin. Since inflammation reactions inevitably occur in the place where the perfusion system penetrates the skin, the hollow fibers package has to be displaced at least every two weeks, which involves new surgery. Consequently, the practical usability of his system as a wearable sensor for continuous determination of glucose is very limited.

The object of the invention is to provide a wearable glucose sensor avoiding these drawbacks and particularly capable of being easily applied by the user himself and continuously giving reliable measuring results on the basis of which the administration of medicines, such as insulin, in response to the actually prevailing glucose concentration can be regulated without requiring frequent replacements of component parts, especially of parts applied under the skin.

This object is achieved according to the invention by a process of the type defined in the opening paragraph, which is characterized in that a perfusion fluid which contains dissolved glucose oxidase, or in which glucose oxidase is dissolved before reaching the measuring cell, is passed continuously or intermittently at a constant rate via a supply tube through a hollow fiber provided in the subcutaneous tissue and permeable to glucose and is passed via an airtight discharge tube from the hollow fiber to a measuring cell provided outside the body, with a dialysis taking place subcutaneously whereby glucose passes via the wall of the hollow fiber from the tissue into the perfusion fluid in an amount proportional to the locally prevailing glucose concentration, and with the glucose received in the perfusion fluid being completely oxidized before reaching the measuring cell.

In this connection it is preferred according to the invention that the used amount of oxygen

-6-


is measured and that a measuring cell is used which comprises an operating electrode, an electrolyte space filled with electrolyte and a reference electrode and the perfusion fluid is passed along the measuring cell via a flow chamber provided in a flow element, said flow chamber having an inlet for the perfusion fluid discharged from the hollow fiber and an outlet for the perfusion fluid and being separated from the measuring cell by a membrane permeable to oxygen gas. As regards the measuring cell, it is preferred that an operating electrode of a noble metal, such as gold, silver and preferably platinum, and a reference electrode of silver are used, the electrolyte employed is a potassium phosphate buffer, preferably 0.5 M  $K_2HPO_4$ , the employed membrane permeable to oxygen gas is a hydrophobic membrane, preferably a Teflon membrane, and a voltage negative with respect to the reference electrode of about 0.6 V is applied to the operating electrode.

As every biosensor the new wearable glucose sensor according to the invention consists of a "selector" portion and a "detector" portion.

The selector portion, namely, the perfusion system, ensures that only glucose is measured from the plurality of substances circulating in the body; then the amount is determined by means of the detector, namely, the measuring cell.

For the selector two membranes and the enzyme glucose oxidase (GOD) are used, and the detector employed is an electrode giving an electric signal.

The principle of the glucose sensor is known and is based on the following reaction:



The electrode measures the amount of  $O_2$  remaining from the reaction or the resultant amount of  $H_2O_2$  depending



-7-

on the voltage applied to the electrode.

The selector employed by the glucose sensor according to the invention is a perfusion system which includes a subcutaneous dialysis step in which glucose  
5 diffuses from the subcutaneous tissue through the wall of the hollow fiber into the dialysis fluid in which the reaction catalyzed by the enzyme between glucose and oxygen takes place. This subcutaneous dialysis step is absent in the known glucose sensors, except  
10 for that of Bombardieri. With Bombardieri, however, the reaction step by means of non-immobilized enzyme in the perfusion system is absent.

The dialysis step is deemed necessary for a reliable glucose sensor on an enzymatic basis for  
15 the following reasons:

1) The  $O_2$  concentration (saturated in water or body fluid) is not sufficient to completely convert physiological glucose concentrations by means of the enzyme. At glucose concentrations of 100 mg/dl or more  
20 the  $O_2$  concentration is already zero and glucose is no longer measurable. Therefore, the glucose concentration must be diluted with respect to the  $O_2$  concentration in the measuring fluid. This is only achieved by the subcutaneous dialysis system according to the invention  
25 in which a short hollow fiber is used. The use of a short hollow fiber according to the invention has the additional advantage that it can be easily applied by the user himself by means of a needle.

2) The enzyme GOD has a high breakdown rate at  
30  $37^\circ C$  and continuous measurement. It is therefore necessary to use new enzyme every day or every two days. This can be easily done by means of the dialysis system according to the invention without requiring replacement of component parts applied under the skin.

35 In various modifications of the invention there can be used, e.g., an enzyme metering device

-8-

located outside the body which ensures automatic supply of solid enzyme to the perfusion fluid in which enzyme is to be dissolved. Thus the breakdown problem is easily avoided and a long service life can be realized without intermediate enzyme replacement of, e.g., at least two and a half months. In other modifications of the invention there is used a reservoir filled with perfusion fluid, which is located outside the body and can be easily replaced by a new reservoir filled with perfusion fluid.

As stated before, the used amount of oxygen is preferably measured according to the invention. This has the advantage that less stringent requirements need to be imposed on the quality of the employed enzyme. If the glucose sensor would be based on a measurement of the resultant amount of hydrogen peroxide, traces of the enzyme catalase which catalyzes the breakdown of hydrogen peroxide could adversely affect the accuracy of the measurement. However, when the used amount of oxygen is measured, the presence of catalase is favorable and some modifications of the invention therefore use a perfusion fluid containing both glucose oxidase and catalase. A second problem associated with a measurement of the resultant amount of hydrogen peroxide is that the dialysis fluid containing the  $H_2O_2$  formed is to be immediately contacted with the electrode resulting in that other substances in the dialysis fluid may have a disturbing effect on the measurement. This last-mentioned drawback may perhaps be removed by using special membranes, e.g., specific cellulose ester membranes, but a perfect separation of dialysis fluid and electrode which only allows hydrogen peroxide to pass is hard to realize. If, however, the used amount of oxygen is measured, the dialysis fluid can be perfectly kept separated from the electrode by means of a membrane which is only permeable to gases, such as a Teflon membrane, and the measurement can be carried out in

-9-

a well defined electrolyte, such as a potassium phosphate buffer of 0.5 M  $K_2HPO_4$ .

A number of modifications of the process according to the invention is characterized in that the perfusion fluid is supplied through an airtight supply tube, preferably of polyethylene, or through an air-permeable supply tube, preferably of Teflon or silicone rubber, from a reservoir provided outside the body and is discharged after passing through the measuring cell to a receptacle likewise provided outside the body.

Such a process can be carried out, e.g., in such a manner that the employed perfusion fluid supplied from the reservoir is a physiological saline solution which is contacted outside the body with glucose oxidase after passing through the hollow fiber and before passing through the measuring cell.

Such a process, however, is preferably carried out in such a manner that the employed perfusion fluid supplied from the reservoir is a solution of glucose oxidase in a physiological saline solution. It is then preferred that the perfusion fluid contains at least 0.05 mg, preferably at least 0.10 mg glucose oxidase per ml physiological saline solution, and preferably 0.20-0.40 mg glucose oxidase per ml. The flow rate of the perfusion fluid will preferably be 0.1-1.0 ml/hour, and most preferably 0.2-0.4 ml/hour.

A much preferred modification of the process according to the invention in which a circulation of perfusion fluid is used is characterized in that the perfusion fluid employed is a physiological saline solution containing the enzymes glucose oxidase and catalase in the dissolved state, the perfusion fluid is returned after passing through the measuring cell to the hollow fiber via a system comprising at least one air-permeable part, and before or after passing through the measuring cell the perfusion fluid is passed

-10-

through an enzyme metering device provided outside the body, in which device a new amount of glucose oxidase and catalase is dissolved in the perfusion fluid.

It is then preferred that after passing through  
5 the measuring cell the perfusion fluid is returned to the hollow fiber via an air-permeable supply tube, preferably of Teflon or silicone rubber. It is further preferred that the perfusion fluid contains at least 0.05 mg, preferably at least 0.10 mg glucose oxidase  
10 and at least 0.05 mg, preferably at least 0.10 mg catalase per ml physiological saline solution, and most preferably that the perfusion fluid contains 0.20-0.40 mg glucose oxidase and 0.20-0.40 mg catalase per ml.

The hollow fiber required for the dialysis  
15 step must pass glucose. It is preferred that a hollow fiber of cellulose ester (such as cellulose acetate) having a molecular weight cut off value of about 10 kD is used. However, other types of materials are also useful, such as hollow fibers of polysulfone or acrylic  
20 copolymer (Amicon). The preferred cellulose fiber, however, is stronger and more flexible and can be inserted into the body more easily than the thicker and more vulnerable Amicon fiber.

As regards sizes, it is preferred that a hollow  
25 fiber is used having an inner diameter of 100-500  $\mu\text{m}$ , preferably 120-200  $\mu\text{m}$ , an outer diameter of 130-550  $\mu\text{m}$ , preferably 150-250  $\mu\text{m}$ , and is 0.1-3 cm, preferably 0.5-2.5 cm, in length. Also, the nature of the supply and discharge tubes is not critical, provided, anyhow,  
30 the discharge tube is airtight. Polyethylene tubes are preferred in the case of airtight tubes and a Teflon or silicone rubber tube in the case of an air-permeable supply tube. As for their sizes, it is preferred that the supply and discharge tubes have an inner diameter  
35 of 0.2-0.6 mm, preferably 0.25-0.35 mm, and an outer diameter of 0.4-1.0 mm, preferably 0.6-0.8 mm.

The length of the airtight discharge tube between the hollow fiber and the flow chamber must

-11-

preferably be as short as possible, so as to enable a rapid response. It is preferred that the airtight discharge tube between the hollow fiber and the flow chamber is 1-10 cm, preferably 1-5 cm, in length.

5 As regards the flow element, it is preferred in connection with a high accuracy of the glucose sensor that a flow chamber is used having such sizes, shape and position of the perfusion fluid inlet and outlet that substantially no dead spaces occur. The exposed  
10 surface of the operating electrode which is separated from the perfusion fluid by the membrane permeable to oxygen (or to  $H_2O_2$ ) may be transverse to the direction of flow the perfusion fluid or may also be in line with the perfusion fluid inlet opening, the distance  
15 between the inlet opening and the exposed surface of the operating electrode being preferably less than 5 mm, and most preferably less than 1 mm.

The nature of the reservoir for perfusion fluid, if used, is not critical, on condition that it  
20 has a drive mechanism (pump) with which the perfusion fluid contained therein can be pressed through the supply tube connected thereto at a constant rate. The receptacle employed is preferably a plastic bag.

In some modifications use is made of an enzyme  
25 metering device. By this is generally meant a system capable of keeping the concentration of enzymes (glucose oxidase and catalase) constant in the glucose sensor with a fully closed circuit, the object of which is to enable reliable continuous measurements of the subcutaneous glucose level without replacements at the sensor,  
30 for a longer period of time.

While in case of an open-circuit sensor the reservoir with enzyme-containing perfusion fluid must be replaced by the user every two days, the enzyme  
35 metering device can automatically adopt this task in the closed-circuit sensor, and as in physiological

-12-

processes, said device can supplement the amount of enzymes broken down.

Different modifications of an enzyme metering system are conceivable:

5 a) Slow-release tablets:

The enzymes (glucose oxidase and catalase) can be tableted together with noninterfering adjuvants suitable therefor, the tablets releasing the active ingredients (in the presence case the enzymes) slowly  
10 to the solvent.

Tablets having different release profiles already exist and can be adapted for the release of enzymes. By introducing a suitable enzyme-release tablet into a reservoir from which the perfusion fluid  
15 is circulated, the concentration of enzymes can be kept intact for a long period of time. Even a mechanical system is conceivable which releases a new tablet in the reservoir at given times.

b) Hollow fiber system:

20 The enzyme release to the perfusion system, can also be effected with a hollow fiber. The molecular weight of glucose oxidase is 119,000; by selecting a hollow fiber having a molecular weight cut off of about 100,000, it is possible to have the enzyme  
25 diffuse slowly therethrough. The enzyme is then contained in solid form in an enclosed space outside the hollow fiber, and the perfusion fluid flows through the hollow fiber. The molecular weight cut off and the length of the fiber determine the amount  
30 of enzyme released to the perfusion system per unit of time.

After optimization of these parameters there is formed a passive release system which can keep the concentration of the enzyme constant.

35 Also in the case of the closed system (perfusion fluid circulation) there can be used a reservoir for perfusion fluid. The reservoir and the enzyme

-13-

metering device are preferably combined in one component part.

The invention is further embodied in a system for continuously or intermittently determining the glucose concentration in subcutaneous tissue, characterized by

- a hollow fiber permeable to glucose;
- a supply tube for perfusion fluid;
- an airtight discharge tube for perfusion fluid;

10 and

- a measuring cell for measuring the amount of oxygen or the amount of hydrogen peroxide in the perfusion fluid.

Such a system can further be characterized by a reservoir for perfusion fluid provided with a device for passing perfusion fluid contained in the reservoir through the hollow fiber at a constant rate via the supply tube connected to the reservoir; a receptacle for employed perfusion fluid; and, if desired, a perfusion fluid contained in the reservoir, said fluid consisting of a solution of glucose oxidase in a physiological saline solution; or can further be characterized by an air-permeable supply tube for perfusion fluid; an enzyme metering device; a pump for circulating perfusion fluid at a constant rate; if desired, a supply contained in the enzyme metering device of the enzymes glucose oxidase and catalase in solid form; and, if desired, an amount of perfusion fluid consisting of a solution of the enzymes glucose oxidase and catalase in a physiological saline solution.

The invention is also embodied in a measuring cell assembly suitable for use in this system, which is characterized by a measuring cell comprising an operating electrode, an electrolyte space and a reference electrode, as well as a pertaining flow element for

-14-

for  
perfusion fluid comprising an inlet and an outlet/perfusion  
fluid which communicate with a flow chamber capable  
of being separated from the measuring cell by an oxygen  
gas-permeable membrane.

5           The invention is further embodied in an assembly  
for continuously or intermittently regulating the glucose  
content in blood, which is characterized by a system  
for continuously or intermittently determining the  
glucose concentration in subcutaneous tissue as defined  
10 above, as well as a regulable injection system for  
introducing medicines, such as insulin, into the blood;  
and a calculating and regulating system for calculating  
the glucose concentration in the subcutaneous tissue  
on the basis of the measuring values of the measuring  
15 cell and a pertaining calibration curve, by means of  
an algorithm, the characteristic and relevant parameters  
of which are contained in a mathematical model, determining  
the amount of medicine to be supplied and controlling  
the regulable injection system in such a manner that  
20 the glucose concentration in the tissue and/or in the  
blood remains within predetermined values. Preferably,  
the calculating unit also has alarm function in case  
of extreme glucose concentrations in the body and in  
case of failures. The calculating unit can also have  
25 the secondary task of monitoring the curve of the memory  
concentration and insulin supply, storing same in the  
local memory and transporting same upon command of  
an external system to other data processing systems.

          In the following the invention will be explained  
30 with reference to the accompanying drawings and by  
means of a description of conducted experiments.  
In the drawings:

Fig. 1 is diagrammatic cross-sectional view  
of a wearable glucose sensor according to the invention;

35           Fig. 2 is a diagrammatic cross-sectional view  
of a measuring cell assembly according to the invention;



-15-

fig. 3 is a diagrammatic cross-sectional view of a hollow fiber of polyacrylate mounted on a needle;

fig. 4 is a diagrammatic representation of a wearable glucose sensor according to the invention in which a perfusion fluid circulation is used;

figs. 5-13 are graphically plotted results of in vitro and in vivo experiments.

As diagrammatically shown in Fig. 1, the system according to the invention for continuously determining the glucose concentration in subcutaneous tissue comprises a hollow fiber (2) to be applied under the skin (1), said hollow fiber being connected via an airtight supply tube (3) and an airtight discharge tube (4) to component parts located outside the body. The supply tube (3) can be connected to a reservoir (5) for perfusion fluid, a device (7) driven by a pump (6) being provided to force the perfusion fluid contained in the reservoir through the hollow fiber at a constant rate via the supply tube. The supply tube (4) can be connected to the perfusion fluid inlet of a flow element (8), the perfusion fluid outlet of which is connected via a tube (9) to a receptable (10) for employed perfusion fluid. Connected to the flow element (8) is a measuring cell (11) also referred to as electrode, said measuring cell being connected to a potentiostat (12).

Of course, modifications other than those shown in Fig. 1 are possible too. Thus, for instance, it is not necessary that the supply tube and the discharge tube pass through the skin in different places and that the hollow fiber extends in one direction only. When a looped hollow fiber is used, one hole in the skin will suffice for supply and discharge purposes, glued joints in the body can be avoided and stresses, if any, on the hollow fiber caused by a moving person can be avoided too.

As diagrammatically shown in Fig. 2, the measuring

-16-

cell (11) comprises an operating electrode (13) separated by an isolating jacket (14) of, e.g., glass or plastic from a reference electrode (15) adhered to the isolating jacket (14), e.g., by means of an epoxy resin. The

5 operating electrode preferably consists of a platinum wire, the operating surface of which is limited to the tip. The reference electrode preferably consists of a silver sleeve in which an electrode space (16) is milled out. The operating electrode and reference

10 electrode are connected via jacketed current conductors (17) and (18), respectively, to a potentiostat (not shown in Fig. 2). The reference electrode is enclosed within an isolating jacket (19) of, e.g., glass or plastic. As shown in Fig. 2, it is not necessary to

15 jacket the entire outer surface of the reference electrode. At the end of the measuring cell where the exposed operating surface (20) of the operating electrode and the electrolyte space (16) are provided the reference electrode is enclosed within an isolating jacket (21)

20 which is preferably made of glass or a hard plastic, and the outer diameter of which is adapted to the sizes of the flow element (8) (only diagrammatically shown in Fig. 2) in such a manner that the flow element can be pushed fittingly over this isolating jacket (21).

25 The membrane permeable to oxygen gas and impermeable to fluid or the membrane permeable to  $H_2O_2$  which separates the flow chamber for perfusion fluid, as provided within the flow element, from the measuring cell may consist in a preferred embodiment of a separate sheet (22)

30 of, e.g., Teflon in the case of an oxygen electrode which is enclosed between the jacket (21) and the flow element (8) when the flow element advances on the measuring cell. The operating electrode, the reference electrode and the electrolyte space filled with an electrolyte

35 are thereby separated from the space in the flow element

-17-

referred to as flow chamber, through which the perfusion fluid from the hollow fiber is passed. The membrane, however, may also be a fixed part of the measuring cell or may be applied by dip techniques. In the case of the oxygen electrode any hydrophobic membrane that only passes gases is suitable. Indicated in Fig. 2 are further the most important sizes of the miniature measuring cell employed in the experiments, namely a length of about 23 mm and a diameter in the order of magnitude of 5 mm.

The system according to the invention may comprise a hollow fiber having a diameter of 500-1200  $\mu\text{m}$ , preferably 900-1100  $\mu\text{m}$ , such as an Amicon hollow fiber, which, mounted on a needle as shown in Fig. 3, can be directly inserted under the skin. The hollow fiber-on-needle shown in Fig. 3 comprises a supply tube (23), a discharged tube (24), a silicone butterfly (25), a double-lumen outer tube (26), a polysulfone hollow fiber (27), a perfusion fluid turning point (28) and a needle point (29).

Preference, however, is given to hollow fibers of cellulose ester having an external diameter of 150-250  $\mu\text{m}$ , which are preferably used as follows. First of all the hollow fiber is to be positioned. To achieve this, according to a first method a hypodermic needle (1.20 x 40 mm) is inserted through the skin into the subcutaneous fat tissue preferably somewhere on the abdomen (few pain receptors), followed by passing the tip of the needle through the skin again from the inside to the outside. Thus, a guide tube is formed through which the tubing consisting of supply tube (3), hollow fiber (2) and discharge tube (4) is drawn until the hollow fiber is in the needle (the supply and discharge tubes, for instance, are firmly fixed to the hollow fiber with glue). Then the needle is withdrawn so that only the hollow fiber with a small part of the supply and

-18-

discharge tubes remains in the body. Subsequently, the other component parts are connected thereto outside the body. According to a second method a catheter containing a needle is passed through the skin into the subcutaneous fat tissue, followed by withdrawal of the needle. A looped hollow fiber is introduced into the catheter positioned, followed by pushing back the catheter so far that the looped hollow fiber remains in the subcutaneous tissue in exposed condition.

10 In order to make it possible to carry out the subcutaneous dialysis at a constant rate of preferably 0.3 ml/hour, perfusion fluid is passed through the hollow fiber via the supply tube. The perfusion fluid contained in the reservoir (5) is preferably a solution of the enzyme glucose oxidase in a physiological saline solution, e.g., a solution containing 0.25 mg GOD per ml.

The glucose present in the subcutaneous fat tissue diffuses through the wall of the hollow fiber into the perfusion fluid in which the reaction between the glucose and the oxygen takes place with catalysis of the enzyme. Via the discharge tube (4) glued to the other side of the hollow fiber (2) the perfusion fluid is discharged to a miniaturized oxygen electrode located outside the body where the remaining amount of oxygen from the enzymatic reaction is determined and is converted into an electric signal. The dialysis fluid is then discharged to a bag (10). The electrode is connected via a jacketed 2-core cable to a potentiostat (12) which maintains a fixed voltage (- 0.6 V) on the electrode and measures the current strength caused by the oxygen.

30 An alternative, which will not be discussed in more detail, is the use of a physiological saline solution as perfusion fluid in combination with a reaction space containing the enzyme, said space being provided outside the body between the discharge tube (4) and

-19-

the oxygen electrode (11). By passing the perfusion fluid, which in the hollow fiber (2) has received glucose from the tissue, via the discharge tube (4) through this separate reaction space, it can likewise be ensured that the desired reaction takes place before the perfusion fluid reaches the oxygen electrode. Although this variant requires an additional component part, namely, an enzyme-containing separate reaction space, it could be advantageous, because the enzyme remains outside the body.

With the measuring cell specificity to oxygen is obtained by applying a negative voltage of 0.6 V to the operating electrode with respect to the reference electrode. Electrons of the operating electrode will then reduce the oxygen passing through the membrane. The current strength measured with the potentiostat is proportional to the oxygen concentration and is read on the ammeter. The potentiostat is preferably a portable device fed by batteries and provided with a digital output and an analog output (in the case of experiments for determination purposes).

Fig. 4 shows a preferred embodiment of the invention in which the perfusion fluid is not conveyed from a reservoir to a receptacle, as in the embodiment of Fig. 1, but is circulated. Similar reference numerals refer to the component parts already discussed with respect to Fig. 1. A portable pump (30) provides the required circulation of the perfusion fluid. In order to enable a long service life, there is provided an enzyme metering device (31) which automatically releases a new amount of the enzymes glucose oxidase and catalase in solid form to and dissolves it in the passing perfusion fluid and can also provide deaeration, if so desired. Although the presence of catalase ensures that the aggressive hydrogen peroxide formed in the glucose oxidation is rapidly decomposed, it is inevitable that the enzyme activity decreases. By a continuous

-20-

or regular replenishment with a fresh amount of enzyme it can be ensured that the enzyme activity in the perfusion fluid is permanently sufficient to rapidly and completely oxidize all of the absorbed glucose.

- 5           Because it is of course necessary that the perfusion fluid passed through the hollow fiber should always contain the same oxygen concentration, the employed oxygen is to be replenished somewhere after passing through the flow element (8) and before passing through
- 10 the hollow fiber (2). For this purpose at least one air-permeable component part should be present in this part of the system, so that the perfusion fluid can absorb oxygen from the air until the saturation concentration has been reached. This can be realized in a very
- 15 simple manner by means of an air-permeable supply tube (3) or by means of an air-permeable tube between the flow element (8) and the enzyme metering device (31) and/or between the device (31) and the pump (30).

- In the experiments described below, unless
- 20 otherwise mentioned, a tubing was used consisting of polyethylene supply and discharge tubes having an inner diameter of 0.29 mm and an outer diameter of 0.69 mm, and a hollow fiber of "saponified cellulose ester (SCE)" having a molecular weight cut off value (MWCO) of 10 kD,
- 25 an inner diameter (in dry condition) of  $150\text{ }\mu\text{m} \pm 15\text{ }\mu\text{m}$  and an outer diameter (in dry condition) of about  $186\text{ }\mu\text{m}$ . The discharge tube was about 1.5 cm in length.

#### IN VITRO EXPERIMENT

- In this experiment the glucose sensor was
- 30 tested by alternately suspending the hollow fiber which is 10 mm in length in vessels containing water or a glucose solution of a known concentration. An enzyme solution (GOD 0.15 mg/ml) was pumped through the fiber at a rate of 1.05 ml/hour. From the records of the
- 35 recorder connected to the potentiostat the following parameters were derived:

-21-

## RESULTS:

Glucose 100 mg/dl:

	1	2	3	aver.	+/-	S.D.
slope of sensor						
response (slope)	7.5	7.4	8.7	7.87	+/-	0.72
deflection	18.5	21.2	20.1	19.93	+/-	1.36
(parts )						
t 90% (sec.)	156	192	144	174	+/-	25

Glucose 200 mg/dl:

	1	2	3	4	aver.	+/-	S.D.
slope	11.6	15.2	14.8	13.5	13.78	+/-	1.62
deflection							
(parts)	52.5	51.0	46.7	36.5	46.68	+/-	7.21
t 90% (sec)	228	180	192	144	186	+/-	35

Glucose 300 mg/dl:

	1	2	3	4	5	6	7	aver. +/- S.D.
slope	18.2	19.0	18.0	23.0	22.4	18.6	20.2	19.9 +/- 2.40
deflection	59.5	61.8	68.4	57.8	60.2	64.3	65.0	62.3 +/- 3.68
t 90%	192	252	336	120	180	420	180	240 +/- 105



Glucose 400 mg/dl:

	1	2	3	aver.	+/-	S.D.
slope	21.8	24.3	26.6	24.23	+/-	2.40
5 deflection	84.5	84.0	81.0	83.17	+/-	1.89
t 90%	468	156	192	272	+/-	171

In all cases the response time ( $t_{res}$ ) was not more than 1 minute. The response time is the time lapsed between the moment of replacing the water by a glucose solution and the moment the recorder begins to deflect. By  $t_{90\%}$  is meant the time lapsed between the former moment and the moment at which the deflection of the recorder reaches 90% of the plateau value. The slope of the sensor response indicates the rate at which the deflection increases.

Fig. 5 shows the relation between the glucose concentration and the deflection on the recorder. Fig. 6 shows the relation between the glucose concentration and the slope and Fig. 7 the relation between the deflection and the slope.

As appears from Fig. 5, there is a linear relation between the concentration and the deflection. This means that the glucose sensor operates linearly in the concentration range of 0 to 400 mg/dl and that accordingly in this range the sensor signal is a measure of the glucose concentration.

Fig. 6 shows that there is also a linear relation between the glucose concentration and the slope of the sensor response. The fact, however, is that at higher concentrations the determination of the slope becomes increasingly difficult, so that the standard deviation (SD) in question becomes greater and greater. In the case of in vivo measurements this plays no role because the glucose sensor is rapid enough so

-24-

that the plateau values may be used to calculate the glucose concentration. Fig. 7 has shown that there is also a directly proportional relation between the deflection and the slope of an increase. This means  
5 that the slope is a proper measure of the level at which the plateau will adjust.

In the concentration range of 0 to 400 mg/dl the glucose sensor therefore gives a linear signal. This applies to both the slope and the plateau value.  
10

#### IN VIVO EXPERIMENTS:

A) Long-term test on a healthy test subject:

Record:

On day 1 a hollow fiber (1.5 cm in length) is inserted  
15 into a healthy test subject. In order to study whether the sensor still functions well after some days in the body, measuring is started on day 6.

It concerns an open-circuit measurement, i.e. the perfusion fluid is collected and not returned to the hollow fiber.

20 Pump: peristaltic pump Minipuls II

Perfusion rate: 0.3 ml/hr

Enzyme concentration: 0.15 mg/ml

After recording the basal glucose level for some time, glucose is orally administered to the test  
25 subject ( $t = 0$ ). The blood-sugar-level is monitored with the Yellow Springs, and the sensor continuously measures the glucose subcutaneously (Figs. 8, 9 and 10).

day 6: 100 g glucose orally  
30 day 7: 50 g glucose orally  
day 9: 75 g glucose orally.

Figs. 8, 9 and 10 show that the rise of the glucose level in the subcutaneous tissues occurs about 5 minutes later than the rise in the blood. The fall,  
35 too, starts about 5 minutes later. The glucose sensor itself has a response time of less than 1 minute, i.e.

-25-

the delay observed is chiefly a physiological effect. It further appears that during the fall of the glucose levels the level is subcutaneously above the hematic level. An explanation of these observations resides  
5 in the fact that the insulin must first distribute over the bloodstream after which it inhibits the release of glucose by the liver. This results in that the blood-sugar-level sinks. The insulin diffuses from the blood into the extracellular moisture after which it incites  
10 the cells to accelerate the absorption of glucose. This explains why the fall in the subcutaneous tissues is later and faster than in the blood.

At the end of the test an equilibrium readjusts between the extracellular fluid (subcutaneously) and  
15 blood, so that the concentration is substantially equalized in both compartments.

Therefore, the glucose sensors seems to properly monitor the subcutaneous processes on all three days. The observations are physiologically explainable. Remarkable  
20 is the rather slight delay in the non-diabetic test subject between the changes in the blood and subcutaneously in comparison with diabetics (see the relevant places). This may indicate individual differences, but could also be based on the fact that the differences between  
25 intravascular and extravascular glucose concentrations in the physiological range during a non-steady state are much smaller than in disordered diabetics showing hyperglycemia.

After the experiment on day 9 the hollow fiber  
30 is easily removed from the body in undamaged condition. A small red irritated spot on the abdomen is the only thing that marks the place of insertion.

B) Correlation plot of pilot study on healthy test

-26-

subjects:

Record:

- 100 g glucose is orally administered to 6 healthy test subjects on two successive days. During this oral glucose tolerance test the blood-sugar-level is measured, and furthermore the subcutaneous glucose concentration is monitored with the glucose sensor. The reservoir with enzyme is still a 10 ml syringe here which is exhausted by a pump (Braun VI). The perfusate is collected so that the circuit is not closed.
- Perfusion rate: 0.3 ml/hr  
Enzyme concentration: 0.15 mg/ml  
Fiber length: 15 mm

- The subcutaneous and the blood sugar values of the rising as well as the sinking parts of the curves are all plotted together (Fig. 11). The resulting diagram shows the correlation between blood and sensor values ( $r = 0.8807$ ,  $n = 135$ ). The spreading between the different points is also an indication of the physiological delay between both compartments for which no correction is made here.

C) Pilot study on diabetics:

Record:

- The patients take breakfast in the morning, but do not inject insulin so that the tests are started with a high blood-sugar-level. After recording the subcutaneous sugar level with the glucose sensor (check by means of blood sugars with the Yellow Springs)  $t = 0$  insulin is administered after which the fall of the glucose level is monitored.

- A totally closed circuit is used in these experiments in which the perfusion fluid is returned to the reservoir (plastic vessel) for repeated use. The discharge tube is connected to the reservoir with an air-permeable tube (Teflon) in order to reinstate the oxygen concentration of the perfusion fluid. Catalase is also added

-27-

to the perfusion fluid in order to remove the hydrogen peroxide formed.

Perfusion rate: 0.3 - 1.2 ml/hr

Fiber length: 15 mm

5 Enzyme concentration: 0.3 mg/ml (GOD and catalase)

An example of such a recording is fig. 12 in which the fall is clearly visible as well as the physiological delay ensuring that the sensor signal will fall somewhat later. This physiological delay 10 differs from 5 to 20 minutes among the 11 diabetics.

The glucose values of the falling parts of the curves of all of the 11 diabetics are again plotted together in a diagram (Fig. 13). The correlation between blood and sensor values is found to be 0.9450, which 15 proves that the sensor monitors the sugar level excellently.

-28-

Claims

1. A process for continuously or intermittently determining the glucose concentration in subcutaneous tissue, which comprises using an enzymatic oxidation of glucose by oxygen in the presence of the enzyme  
5 glucose oxidase and determining the used amount of oxygen or the resultant amount of hydrogen peroxide by means of a measuring cell, characterized in that a perfusion fluid which contains dissolved glucose oxidase, or in which glucose oxidase is dissolved before  
10 reaching the measuring cell, is passed continuously or intermittently at a constant rate via a supply tube through a hollow fiber provided in the subcutaneous tissue and permeable to glucose and is passed via an airtight discharge tube from the hollow fiber to a  
15 measuring cell provided outside the body, with a dialysis taking place subcutaneously whereby glucose passes via the wall of the hollow fiber from the tissue into the perfusion fluid in an amount proportional to the locally prevailing glucose concentration, and with  
20 the glucose received in the perfusion fluid being completely oxidized before reaching the measuring cell.
2. A process as claimed in claim 1, characterized in that the used amount of oxygen is measured.
3. A process as claimed in claim 2, characterized  
25 in that a measuring cell is used which comprises an operating electrode, an electrolyte space filled with electrolyte and a reference electrode, and the perfusion fluid is passed along the measuring cell via a flow chamber provided in a flow element, said flow chamber  
30 having an inlet for the perfusion fluid discharged from the hollow fiber and an outlet for the perfusion fluid and and being separated from the measuring cell by a membrane permeable to oxygen gas.

4. A process as claimed in claim 3, characterized in that an operating electrode of a noble metal, preferably platinum, and a reference electrode of silver are used, the electrolyte employed is a potassium phosphate buffer, preferably 0.5 M  $K_2HPO_4$ , the employed membrane permeable to oxygen gas is a Teflon membrane, and a voltage negative with respect to the reference electrode of about 0.6 V is applied to the operating electrode.
5. A process as claimed in any of claims 1-4, characterized in that the perfusion fluid is supplied through an airtight supply tube, preferably of polyethylene, or through an air-permeable supply tube, preferably of Teflon or silicone rubber, from a reservoir provided outside the body and is discharged after passing through the measuring cell to a receptacle likewise provided outside the body.
6. A process as claimed in claim 5, characterized in that the employed perfusion fluid supplied from the reservoir is physiological saline solution which is contacted outside the body with glucose oxidase after passing through the hollow fiber and before passing through the measuring cell.
7. A process as claimed in claim 5, characterized in that the employed perfusion fluid supplied from the reservoir is a solution of glucose oxidase in a physiological saline solution.
8. A process as claimed in claim 7, characterized in that the perfusion fluid contains at least 0.05 mg, preferably at least 0.10 mg glucose oxidase per ml physiological saline solution.
9. A process as claimed in claim 7, characterized in that the perfusion fluid contains 0.20-0.40 mg glucose oxidase per ml.
10. A process as claimed in any of claims 2-4, characterized in that the perfusion fluid employed is a physiological saline solution containing the enzymes

-30-

- glucose oxidase and catalase in the dissolved state, the perfusion fluid is returned after passing through the measuring cell to the hollow fiber via a system comprising at least one air-permeable part, and before  
5 or after passing through the measuring cell the perfusion fluid is passed through an enzyme metering device provided outside the body, in which device a new amount of glucose oxidase and catalase is dissolved in the perfusion fluid.
- 10 11. A process as claimed in claim 10, characterized in that after passing through the measuring cell the perfusion fluid is returned to the hollow fiber via an air-permeable supply tube, preferably of Teflon or silicone rubber.
- 15 12. A process as claimed in claim 10 or 11, characterized in that the perfusion fluid contains at least 0.05 mg, preferably at least 0.10 mg glucose oxidase and at least 0.05 mg, preferably at least 0.10 mg catalase per ml physiological saline solution.
- 20 13. A process as claimed in claim 10 or 11, characterized in that the perfusion fluid contains 0.20-0.40 mg glucose oxidase and 0.20-0.40 mg catalase per ml.
14. A process as claimed in any of claims 1-13, characterized in that a hollow fiber of cellulose ester  
25 is used having a molecular weight cut off value of about 10 kD.
15. A process as claimed in any of claims 1-14, characterized in that a hollow fiber is used having an inner diameter of 100-500  $\mu\text{m}$ , preferably 120-200  $\mu\text{m}$ ,  
30 an outer diameter of 130-550  $\mu\text{m}$ , preferably 150-250  $\mu\text{m}$ , and is 0.1-3 cm, preferably 0.5-2.5 cm, in length.
16. A process as claimed in any of claims 1-13, characterized in that a hollow fiber of polysulfone or acrylic copolymer is used.
- 35 17. A process as claimed in claim 16, characterized in that a hollow fiber is used having an inner diameter



-31-

of 500-1200  $\mu\text{m}$ , preferably 900-1100  $\mu\text{m}$ .

18. A process as claimed in any of claims 1-17, characterized in that the employed airtight discharge tube is a polyethylene tube.

5 19. A process as claimed in any of claims 1-18, characterized in that the supply and discharge tubes have an inner diameter of 0.2-0.6 mm, preferably 0.25-0.35 mm, and an outer diameter of 0.4-1.0 mm, preferably 0.6-0.8 mm.

10 20. A process as claimed in any of claims 1-19, characterized in that the airtight discharge tube between the hollow fiber and the flow chamber is 1-10 cm, preferably 1-5 cm, in length.

21. A process as claimed in any of claims 1-20, characterized in that the perfusion fluid inlet of the flow chamber is provided opposite or transversely to the exposed surface of the operating electrode, the distance between the inlet end and the exposed surface of the operating electrode which are separated from each other by the oxygen-permeable membrane being less than 5 mm, preferably less than 1 mm.

22. A process as claimed in any of claims 1-20, characterized in that a flow chamber is used having such sizes, shape and position of the perfusion fluid inlet and outlet that substantially no dead spaces occur.

23. A process as claimed in any of claims 1-22, characterized in that the perfusion fluid is passed at a flow rate of 0.1-1.0 ml/hour, preferably 0.2-0.4 ml/hour.

30 24. A system for continuously or intermittently determining the glucose concentration in subcutaneous tissue, characterized by a glucose-permeable hollow fiber, a supply tube for perfusion fluid; an airtight discharge tube for perfusion fluid; and a measuring cell for measuring the amount of oxygen or the amount of hydrogen peroxide in the perfusion fluid.

35 25. A system as claimed in claim 24, further character-

-32-

- ized by a reservoir for perfusion fluid provided with a device for passing perfusion fluid contained in the reservoir through the hollow fiber at a constant rate via the supply tube connected to the reservoir; and  
5 a reservoir for employed perfusion fluid.
26. A system as claimed in claim 25, further characterized by a perfusion fluid contained in the reservoir and consisting of a solution of glucose oxidase in a physiological saline solution.
- 10 27. A system as claimed in claim 24, further characterized by an air-permeable supply tube for perfusion fluid; an enzyme metering device; and a pump for circulating perfusion fluid at a constant rate.
28. A system as claimed in claim 27, further characterized by a supply contained in the enzyme metering  
15 device of the enzymes glucose oxidase and catalase in solid form.
29. A system as claimed in claim 28, further characterized by an amount of perfusion fluid consisting  
20 of a solution of the enzymes glucose oxidase and catalase in a physiological saline solution.
30. A process as claimed in any of claims 24-29, characterized in that the measuring cell comprises an operating electrode, an electrolyte space, and a  
25 reference electrode and is provided with a pertaining flow element comprising an inlet and an outlet for perfusion fluid which communicate with a flow chamber capable of being separated from the measuring cell by an oxygen gas-permeable membrane.
- 30 31. A system as claimed in claim 30, characterized in that the operating electrode is made of a noble metal, preferably platinum, and the reference electrode is made of silver.
32. A system as claimed in claim 30 or 31, characterized  
35 ized in that the electrolyte space is filled with a potassium phosphate buffer, preferably 0.5 M  $K_2HPO_4$ .

-33-

33. A system as claimed in any of claims 30-32, characterized in that the oxygen gas-permeable membrane is a hydrophobic membrane, preferably made of Teflon.

34. A system as claimed in any of claims 30-33, characterized in that the perfusion fluid inlet of the flow chamber is provided opposite or transversely to the exposed surface of the operating electrode, the distance between the inlet end and the exposed surface of the operating electrode which are separated from each other by the oxygen-permeable membrane being less than 5 mm, preferably less than 1 mm.

35. A system as claimed in any of claims 30-34, characterized in that the flow chamber has such dimensions, shape and position of the perfusion fluid inlet and outlet that substantially no dead spaces are present.

36. A system as claimed in any of claims 24-35, characterized in that the glucose-permeable hollow fiber is made of cellulose ester having a molecular weight cut off value of about 10 kD.

37. A system as claimed in any of claims 24-36, characterized in that the hollow fiber has an inner diameter of 100-500  $\mu\text{m}$ , preferably 120-200  $\mu\text{m}$ , an outer diameter of 130-550  $\mu\text{m}$ , preferably 150-250  $\mu\text{m}$ , and is 0.1-3 cm, preferably 0.5-2.5 cm in length.

38. A system as claimed in any of claims 24-35, characterized in that the glucose-permeable hollow fiber is made of polysulfone or acrylic copolymer.

39. A system as claimed in claim 38, characterized in that the hollow fiber has an inner diameter of 500-1200  $\mu\text{m}$ , preferably 900-110  $\mu\text{m}$ .

40. A system as claimed in any of claims 24-30, characterized in that the airtight discharge tube for perfusion fluid is made of polyethylene.

41. A system as claimed in any of claims 24-40, characterized in that the supply and discharge tubes have an inner diameter of 0.2-0.6 mm, preferably 0.25-

-34-

0.35 mm, and an outer diameter of 0.4-1.0 mm, preferably 0.6-0.8 mm.

42. A system as claimed in any of claims 24-41, characterized in that the airtight discharge tube between  
5 the hollow fiber and the flow chamber is 1-10 cm, preferably 1-5 cm, in length.

43. A measuring cell assembly suitable for use in the system as claimed in any of claims 24-42, characterized by a measuring cell comprising an operating electrode,  
10 an electrolyte space and a reference electrode, as well as a pertaining flow element for perfusion fluid comprising an inlet and an outlet for perfusion fluid which communicate with a flow chamber capable of being separated by an oxygen-gas permeable membrane of the  
15 measuring cell.

44. A measuring cell assembly as claimed in claim 43, characterized in that the operating electrode is made of a noble metal, preferably platinum, and the reference electrode is made of silver.

20 45. A measuring cell assembly as claimed in claim 43 or 44, characterized in that the electrolyte space is filled with a potassium phosphate buffer, preferably 0.5 M  $K_2HPO_4$ .

46. A measuring cell assembly as claimed in any  
25 of claims 43-45, characterized in that the oxygen gas-permeable membrane is a hydrophobic membrane, preferably made of Teflon.

47. A measuring cell assembly as claimed in any of claims 43-46, characterized in that the perfusion  
30 fluid inlet of the flow chamber is provided opposite or transversely to the exposed surface of the operating electrode, the distance between the inlet end and the exposed surface of the operating electrode which are separated from each other by the oxygen-permeable membrane  
35 being less than 5 mm, preferably less than 1 mm.

48. A measuring cell assembly as claimed in any

-35-

of claims 43-47, characterized in that the flow chamber has such sizes, shape and position of the perfusion fluid inlet and outlet that substantially no dead spaces are present.

- 5 49. A measuring cell assembly for continuously or intermittently regulating the glucose concentration in blood, characterized by a system for continuously or intermittently determining the glucose concentration in subcutaneous tissue as claimed in any of claims
- 10 24-42, as well as a regulable injection system for introducing medicines, such as insulin, into the blood; and a calculating and regulating system for calculating the glucose concentration in the subcutaneous tissue on the basis of the measuring values of the measuring
- 15 cell and a pertaining calibration curve, by means of an algorithm, the characteristic and relevant parameters of which are contained in a mathematical model, determining the amount of medicine to be supplied and controlling the regulable injection system in such a manner that
- 20 the glucose concentration in the tissue and/or in the blood remains within predetermined values.

1/11

FIG.1




FIG.2






FIG.3




2/11

FIG. 4




3/11






4/11




5/11



6/11


FIG. 8




7/11

FIG. 9

LONGTERM EXPERIMENT IN VIVO




8/11




9/11

FIG. 11




10/11

IN VIVO EXPERIMENT DP 9




11/11





# INTERNATIONAL SEARCH REPORT

International Application No PCT/NL 88/00039

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (If several classification symbols apply, indicate all) * According to International Patent Classification (IPC) or to both National Classification and IPC IPC <sup>4</sup> : A 61 B 5/00; A 61 M 5/142; C 12 M 1/40								
<b>II. FIELDS SEARCHED</b> <div style="text-align: center;">Minimum Documentation Searched <sup>7</sup></div> <table style="width: 100%; border: none;"> <tr> <td style="width: 25%; border: 1px solid black; padding: 5px;">Classification System</td> <td style="border: none;"></td> <td style="width: 75%; border: 1px solid black; padding: 5px;">Classification Symbols</td> </tr> <tr> <td style="border: 1px solid black; padding: 5px;">IPC<sup>4</sup></td> <td style="border: none;"></td> <td style="border: 1px solid black; padding: 5px;">A 61 B; A 61 F; A 61 M; C 12 M</td> </tr> </table> <p style="text-align: center; font-size: small;">Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched *</p>			Classification System		Classification Symbols	IPC <sup>4</sup>		A 61 B; A 61 F; A 61 M; C 12 M
Classification System		Classification Symbols						
IPC <sup>4</sup>		A 61 B; A 61 F; A 61 M; C 12 M						
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT *</b>								
Category *	Citation of Document, * with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>						
A	EP, A, 0134758 (G. BOMBARDIERI) 20 March 1985 see abstract; page 1, line 24 - page 4, line 9; figure 1 cited in the application --	1,5,6,16, 18,24,28, 38,40,49						
A	FR, A, 2400909 (E. FRESENIUS) 23 March 1979 see page 4, line 24 - page 5, line 23; page 7, line 39 - page 8, line 25; figures 1,2 --	1-3,24,25, 49						
A	GB, A, 2019580 (SIEMENS AG) 31 October 1979 see abstract; page 1, lines 102-112; page 2, lines 83-89; page 2, lines 103-114; page 3, lines 71-100; page 3, line 121 - page 4, line 26; page 4, lines 37-51; figures 1-3 --	3,4,30,31, 43,44						
A	EP, A, 0078590 (CORNING GLASS WORKS) 11 May 1983 see abstract; page 12, line 26 - ./. --	1-4,30-33, 43-46						
<div style="display: flex; justify-content: space-between;"> <div style="width: 48%;"> <p>* Special categories of cited documents: <sup>10</sup></p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (see specification)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 48%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"Z" document member of the same patent family</p> </div> </div>								
<b>IV. CERTIFICATION</b>								
Date of the Actual Completion of the International Search <div style="text-align: center;">9th January 1989</div>		Date of Mailing of this International Search Report <div style="text-align: center;">20. 01. 89</div>						
International Searching Authority <div style="text-align: center;">EUROPEAN PATENT OFFICE</div>		Signature of Authorized Officer <div style="text-align: center;">   <b>P.C.G. VAN DER PUTTEN</b> </div>						

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
	page 15, line 30; figures 6-13 --	
A	WO, A, 81/01794 (S.R. ASH) 9 July 1981 see abstract; page 4, line 7 - page 5, line 13; page 10, line 28 - page 11, line 19; page 16, lines 7-18; page 28, line 6 - page 30, line 17; page 32, lines 6-32; figures 4,10-19 --	1-4,49
A	US, A, 4311789 (U.T.G. NYLEN et al.) 19 January 1982 see abstract; column 1, lines 41-46; column 2, lines 3-19; column 3, lines 25-35,56-60; column 4, lines 8-59; column 5, lines 5-33; figures 1-8 --	1-3,14,21, 22,24,25, 34-36,47- 50
A	US, A, 3334623 (D.R. HILLIER) 8 August 1967 see column 2, lines 33-42, 52-72; column 3, lines 1-13, 28-34; figure 2 --	6,21,33
A	Diabetes Care, volume 5, no. 3, May/ June 1982, (New York, US), T. Kondo et al.: "A miniature glucose sensor, implantable in the blood stream", pages 218-221 see pages 218-219, paragraph: "Principle and methods" --	1-5,10, 24,28,31- 33,44-46
A	EP, A, 0104935 (THE YELLOW SPRINGS INSTRUMENT CO. LTD) 4 April 1984 see abstract; page 4, line 25 - page 5, line 8; page 5, line 31 - page 8, line 28; figures 1-4 -----	1-4,21, 22,30,31, 34,35,43, 44,47,48

# ANNEX TO THE INTERNATIONAL SEARCH REPORT ON INTERNATIONAL PATENT APPLICATION NO.

NL 8800039  
SA 24478

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 13/01/89. The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A- 0134758	20-03-85	US-A- 4633878	06-01-87
FR-A- 2400909	23-03-79	GB-A, B 2004092 DE-A- 2737922 JP-A- 54044394 US-A- 4253456	21-03-79 08-03-79 07-04-79 03-03-81
GB-A- 2019580	31-10-79	FR-A, B 2423778 DE-A, C 2817363 CA-A- 1127240 US-A- 4366033 SE-A- 7903393 SE-B- 439378	16-11-79 31-10-79 06-07-82 28-12-82 21-10-79 10-06-85
EP-A- 0078590	11-05-83	GB-A- 2111215 US-A- 4514276	29-06-83 30-04-85
WO-A- 8101794	09-07-81	EP-A, B 0042431 GB-A, B 2082331 SE-A- 8105081 AU-A- 6779481 US-A- 4403984	30-12-81 03-03-82 27-08-81 22-07-81 13-09-83
US-A- 4311789	19-01-82	FR-A, B 2337341 DE-A- 2658101 AU-A- 2101176 NL-A- 7614448 BE-A- 850006 JP-A- 52085885 AU-B- 504818 CA-A- 1075136 US-A- 4229542 GB-A- 1581353 AT-B- 361131 CH-A- 631546 SE-A- 7600024 SE-B- 396819	29-07-77 14-07-77 06-07-78 04-07-77 15-04-77 16-07-77 01-11-79 08-04-80 21-10-80 10-12-80 25-02-81 13-08-82 02-07-77 03-10-77
US-A- 3334623		None	

